Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2014; 139(41): 2096-2100
DOI: 10.1055/s-0034-1387294
DOI: 10.1055/s-0034-1387294
Kommentar | Commentary
Onkologie, Pneumologie
Molekulargenetische Untersuchungen bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: praktische Relevanz
Molecular genetic tests in advanced non-small cell lung cancer: practical relevanceFurther Information
Publication History
08 April 2014
07 August 2014
Publication Date:
30 September 2014 (online)
![](https://www.thieme-connect.de/media/dmw/201441/lookinside/thumbnails/10.1055-s-0034-1387294-1.jpg)
-
Literatur
- 1 Bergethon K, Shaw AT, Ou S-HI et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870
- 2 Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019
- 3 Crinó L, Kim D, Riely GJ et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011; 29: #7514
- 4 Davies KD, Le AT, Theodoro MF et al. Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clin Cancer Res 2012; 18: 4570-4579
- 5 Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin-paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874
- 6 Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122-1128
- 7 Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1727-1733
- 8 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388
- 9 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations oft the epidermal growth factor receptor (WJTOG3405): an open label randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128
- 10 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
- 11 Mok T, Kim DW, Wu Y-L et al. First-line crizotinib versus pemetrexed−cisplatin or pemetrexed−carboplatin in patients with advanced ALK-positive non‑squamous non-small cell lung cancer: results of a phase III study (PROFILE 1014). Proc ASCO 2014; #8002
- 12 Ou S-HI, Bang Y-J, Camidge DR et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Proc ASCO 2013; # 8032
- 13 Paz-Ares L, Soulières D, Melezínek I et al. Clinical outcomes in lung cancer patients with EGFR mutations: pooled analysis. J Cell Molec Med 2010; 14: 51-69
- 14 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246
- 15 Sequist LV, Yang JC-H, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334
- 16 Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012
- 17 Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer (PROFILE 1007). N Engl J Med 2013; 368: 2385-2394
- 18 Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012; 30 #7508
- 19 Wu YL, Zhou C, Hu CP et al. LUX Lung 6: A randomized open label, Phase III study of Afatinib versus Gemcitabine/Cisplatin as first line treatment for Asian patients with EGFR mutation positive advanced adenocarcinoma of the lung. Lancet Oncol 2014; 15: 213-222
- 20 Yang JC-H, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3342-3350
- 21 Yang J, Sequist L, Schuler M et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). Proc ASCO 2014; #8004
- 22 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised phase 3 study. Lancet Oncol 2011; 12: 735-42